| BMS-540215 |
| (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[1,2-f][1,2,4]triazin-6-yloxy)propan-2-ol |
| (CAS 649735-46-6) |
 |
| Description： |
Brivanib(BMS540215) is an ATP-competitive inhibitor against VEGFR2 with IC50 of 25 nM, moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β.
in vivo: Brivanib displays antitumor activities in H3396 xenograft in athymic mice. At a dose of 60 and 90 mg/kg (p.o.), Brivanib completely inhibits the tumor growth, with TGI of 85% and 97%, respectively [1]. Moreover, Brivanib significantly suppresses tumor growth in Hepatocellular carcinoma (HCC) xenografts, which due to the decrease in phosphorylation of VEGFR2. The results show that the tumor weights in 06-0606 xenograft mice are 55% and 13%, compared with the controls at a dose of 50 mg/kg and 100 mg/kg. Brivanib is suggested to be efficient in treatment of HCC [2]. |
| Product No. |
KT20012 |
| Product Name |
BMS-540215 |
| Synonyms |
Brivanib |
| Formal Name |
(R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[1,2-f][1,2,4]triazin-6-yloxy)propan-2-ol |
| CAS Number |
649735-46-6 |
| Molecular Formula |
C19H19FN4O3 |
| Formula Weight |
370.38 |
| Formulation |
A crystalline solid |
| Purity |
98%min |
| Stability |
1 year |
| Storage |
-20°C |
| Shipping |
USD45 for Europe and USA. No shipping charge once amount reach USD500. |
| Quality Control |
HNMR,CNMR,LCMS,HPLC,IR,etc. |
| Price & Availability |
In Stock. Price Negotiated. |
|
| Related Products： |
Apatinib
Axitinib
AZD2932
BIBF 1120
BMS-690514
Bosutinib
Erlotinib
Mubritinib
Pelitinb |
|
